Interpace Biosciences Net Income
| IDXG Stock | USD 1.85 0.03 1.65% |
As of the 15th of February 2026, Interpace Biosciences retains the Risk Adjusted Performance of 0.127, downside deviation of 7.17, and Market Risk Adjusted Performance of (0.55). Interpace Biosciences technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We have analyzed and interpolated nineteen technical drivers for Interpace Biosciences, which can be compared to its competitors. Please check out Interpace Biosciences information ratio, potential upside, as well as the relationship between the Potential Upside and kurtosis to decide if Interpace Biosciences is priced fairly, providing market reflects its last-minute price of 1.85 per share. Please also validate Interpace Biosciences total risk alpha, which is currently at 0.6556 to confirm the company can sustain itself at a future point.
Interpace Biosciences' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Interpace Biosciences' valuation are provided below:Interpace Biosciences does not presently have any fundamental trends for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Interpace |
Interpace Biosciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Interpace Biosciences' otc stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Interpace Biosciences.
| 11/17/2025 |
| 02/15/2026 |
If you would invest 0.00 in Interpace Biosciences on November 17, 2025 and sell it all today you would earn a total of 0.00 from holding Interpace Biosciences or generate 0.0% return on investment in Interpace Biosciences over 90 days. Interpace Biosciences is related to or competes with Unidoc Health, and Devonian Health. Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating c... More
Interpace Biosciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Interpace Biosciences' otc stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Interpace Biosciences upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 7.17 | |||
| Information Ratio | 0.1386 | |||
| Maximum Drawdown | 54.19 | |||
| Value At Risk | (10.71) | |||
| Potential Upside | 15.79 |
Interpace Biosciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Interpace Biosciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Interpace Biosciences' standard deviation. In reality, there are many statistical measures that can use Interpace Biosciences historical prices to predict the future Interpace Biosciences' volatility.| Risk Adjusted Performance | 0.127 | |||
| Jensen Alpha | 1.49 | |||
| Total Risk Alpha | 0.6556 | |||
| Sortino Ratio | 0.179 | |||
| Treynor Ratio | (0.56) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Interpace Biosciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Interpace Biosciences February 15, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.127 | |||
| Market Risk Adjusted Performance | (0.55) | |||
| Mean Deviation | 6.32 | |||
| Semi Deviation | 5.6 | |||
| Downside Deviation | 7.17 | |||
| Coefficient Of Variation | 684.33 | |||
| Standard Deviation | 9.26 | |||
| Variance | 85.82 | |||
| Information Ratio | 0.1386 | |||
| Jensen Alpha | 1.49 | |||
| Total Risk Alpha | 0.6556 | |||
| Sortino Ratio | 0.179 | |||
| Treynor Ratio | (0.56) | |||
| Maximum Drawdown | 54.19 | |||
| Value At Risk | (10.71) | |||
| Potential Upside | 15.79 | |||
| Downside Variance | 51.43 | |||
| Semi Variance | 31.37 | |||
| Expected Short fall | (8.49) | |||
| Skewness | 1.67 | |||
| Kurtosis | 5.8 |
Interpace Biosciences Backtested Returns
Interpace Biosciences is abnormally volatile given 3 months investment horizon. Interpace Biosciences holds Efficiency (Sharpe) Ratio of 0.15, which attests that the entity had a 0.15 % return per unit of risk over the last 3 months. We have analyzed and interpolated twenty-nine different technical indicators, which can help you to evaluate if expected returns of 1.4% are justified by taking the suggested risk. Use Interpace Biosciences Risk Adjusted Performance of 0.127, market risk adjusted performance of (0.55), and Downside Deviation of 7.17 to evaluate company specific risk that cannot be diversified away. Interpace Biosciences holds a performance score of 11 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of -2.38, which attests to a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Interpace Biosciences are expected to decrease by larger amounts. On the other hand, during market turmoil, Interpace Biosciences is expected to outperform it. Use Interpace Biosciences potential upside, as well as the relationship between the kurtosis and day typical price , to analyze future returns on Interpace Biosciences.
Auto-correlation | 0.70 |
Good predictability
Interpace Biosciences has good predictability. Overlapping area represents the amount of predictability between Interpace Biosciences time series from 17th of November 2025 to 1st of January 2026 and 1st of January 2026 to 15th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Interpace Biosciences price movement. The serial correlation of 0.7 indicates that around 70.0% of current Interpace Biosciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.7 | |
| Spearman Rank Test | 0.56 | |
| Residual Average | 0.0 | |
| Price Variance | 0.09 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Interpace Biosciences reported net income of (14.94 Million). This is 104.38% lower than that of the Health Care Providers & Services sector and 108.63% lower than that of the Health Care industry. The net income for all United States stocks is 102.62% higher than that of the company.
Interpace Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Interpace Biosciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Interpace Biosciences could also be used in its relative valuation, which is a method of valuing Interpace Biosciences by comparing valuation metrics of similar companies.Interpace Biosciences is currently under evaluation in net income category among its peers.
Interpace Fundamentals
| Return On Equity | -2.85 | |||
| Return On Asset | -0.26 | |||
| Profit Margin | (0.59) % | |||
| Operating Margin | (0.28) % | |||
| Current Valuation | 11.72 M | |||
| Shares Outstanding | 4.27 M | |||
| Shares Owned By Insiders | 28.12 % | |||
| Number Of Shares Shorted | 47.35 K | |||
| Price To Earning | (1.07) X | |||
| Price To Book | 10.04 X | |||
| Price To Sales | 0.10 X | |||
| Revenue | 41.31 M | |||
| Gross Profit | 17.95 M | |||
| EBITDA | (9.12 M) | |||
| Net Income | (14.94 M) | |||
| Cash And Equivalents | 1.86 M | |||
| Cash Per Share | 0.44 X | |||
| Total Debt | 9.44 M | |||
| Debt To Equity | 6.55 % | |||
| Current Ratio | 0.61 X | |||
| Book Value Per Share | (14.51) X | |||
| Cash Flow From Operations | (8.72 M) | |||
| Short Ratio | 0.19 X | |||
| Earnings Per Share | (3.12) X | |||
| Target Price | 11.0 | |||
| Number Of Employees | 147 | |||
| Beta | 0.82 | |||
| Market Capitalization | 5.16 M | |||
| Total Asset | 38.43 M | |||
| Retained Earnings | (172.59 M) | |||
| Working Capital | (4.21 M) | |||
| Current Asset | 19.16 M | |||
| Current Liabilities | 23.37 M | |||
| Z Score | -4.6 | |||
| Net Asset | 38.43 M |
About Interpace Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Interpace Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Interpace Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Interpace Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Interpace OTC Stock
Interpace Biosciences financial ratios help investors to determine whether Interpace OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Interpace with respect to the benefits of owning Interpace Biosciences security.